The MagCapturer circulating tumor blood cell separator is a laboratory instrument built to isolate and enrich circulating tumor cells (CTCs) from a peripheral blood sample. CTCs are cancer cells that detach from a primary or metastatic tumor and enter the bloodstream, and they are present at extremely low frequency compared with normal blood cells. Capturing them reliably is the first step in many liquid biopsy workflows, where the goal is to obtain a pure CTC fraction for downstream analysis rather than studying the bulk blood.
The device relies on immunomagnetic separation. Magnetic beads are coated with antibodies that recognize surface markers commonly expressed on epithelial tumor cells, such as EpCAM. When a processed blood sample passes through the capture chamber, these labelled beads bind to target cells. A magnetic field then holds the bound cells in place while unbound blood components are washed away, leaving an enriched CTC fraction on the substrate.
This positive-selection approach is valued because it concentrates rare cells instead of merely depleting the abundant leukocyte population. The captured cells remain attached to the solid phase, which simplifies recovery and keeps the sample organized for imaging or molecular work.
A single tube of blood can contain billions of normal cells and only a handful of CTCs. Without enrichment, any downstream measurement would be overwhelmed by background noise. By raising the proportion of tumor cells in the final preparation, the separator improves the signal that sequencing, fluorescence, or cytological methods must detect.
Enrichment also reduces reagent consumption in follow-up assays, because technicians can focus reagents on a small, relevant fraction. For research labs, this translates into cleaner data and more reproducible counts across repeated draws from the same subject.
In practice, whole blood is introduced into the instrument, and the system performs labeling, magnetic capture, and washing in a contained pathway. Because the method is designed to preserve cell integrity, the recovered CTCs can be used for immunofluorescence staining, nucleic-acid extraction, or short-term culture, depending on the study plan.
Laboratories should validate the recovery range with spiked controls before routine use, since recovery can vary with sample volume and handling time. Consistent pre-analytical practice is what turns the hardware into a dependable part of a longitudinal monitoring program.
Q: What sample type does the MagCapturer separator process? A: It is designed for peripheral whole blood samples collected in standard blood tubes, which are then processed inside the instrument for CTC capture.
Q: Which cell markers does the immunomagnetic method target? A: The capture typically uses antibodies against epithelial markers such as EpCAM that are expressed on many carcinoma-derived circulating tumor cells.
Q: Can the isolated cells be used for molecular testing? A: Yes, the preserved fraction is compatible with downstream staining, DNA or RNA extraction, and other laboratory analyses once recovered.
Q: Does the device replace a full pathology report? A: No, it is a sample-preparation instrument that supplies enriched material; clinical interpretation still depends on accredited laboratory assessment.
The MagCapturer circulating tumor blood cell separator is a laboratory instrument built to isolate and enrich circulating tumor cells (CTCs) from a peripheral blood sample. CTCs are cancer cells that detach from a primary or metastatic tumor and enter the bloodstream, and they are present at extremely low frequency compared with normal blood cells. Capturing them reliably is the first step in many liquid biopsy workflows, where the goal is to obtain a pure CTC fraction for downstream analysis rather than studying the bulk blood.
The device relies on immunomagnetic separation. Magnetic beads are coated with antibodies that recognize surface markers commonly expressed on epithelial tumor cells, such as EpCAM. When a processed blood sample passes through the capture chamber, these labelled beads bind to target cells. A magnetic field then holds the bound cells in place while unbound blood components are washed away, leaving an enriched CTC fraction on the substrate.
This positive-selection approach is valued because it concentrates rare cells instead of merely depleting the abundant leukocyte population. The captured cells remain attached to the solid phase, which simplifies recovery and keeps the sample organized for imaging or molecular work.
A single tube of blood can contain billions of normal cells and only a handful of CTCs. Without enrichment, any downstream measurement would be overwhelmed by background noise. By raising the proportion of tumor cells in the final preparation, the separator improves the signal that sequencing, fluorescence, or cytological methods must detect.
Enrichment also reduces reagent consumption in follow-up assays, because technicians can focus reagents on a small, relevant fraction. For research labs, this translates into cleaner data and more reproducible counts across repeated draws from the same subject.
In practice, whole blood is introduced into the instrument, and the system performs labeling, magnetic capture, and washing in a contained pathway. Because the method is designed to preserve cell integrity, the recovered CTCs can be used for immunofluorescence staining, nucleic-acid extraction, or short-term culture, depending on the study plan.
Laboratories should validate the recovery range with spiked controls before routine use, since recovery can vary with sample volume and handling time. Consistent pre-analytical practice is what turns the hardware into a dependable part of a longitudinal monitoring program.
Q: What sample type does the MagCapturer separator process? A: It is designed for peripheral whole blood samples collected in standard blood tubes, which are then processed inside the instrument for CTC capture.
Q: Which cell markers does the immunomagnetic method target? A: The capture typically uses antibodies against epithelial markers such as EpCAM that are expressed on many carcinoma-derived circulating tumor cells.
Q: Can the isolated cells be used for molecular testing? A: Yes, the preserved fraction is compatible with downstream staining, DNA or RNA extraction, and other laboratory analyses once recovered.
Q: Does the device replace a full pathology report? A: No, it is a sample-preparation instrument that supplies enriched material; clinical interpretation still depends on accredited laboratory assessment.
english
français
Deutsch
Italiano
Русский
Español
português
Nederlandse
ελληνικά
日本語
한국
العربية
हिन्दी
Türkçe
indonesia
tiếng Việt
ไทย
বাংলা
فارسی
polski
